Shopping Cart
Remove All
Your shopping cart is currently empty
Tildrakizumab (Synonyms: SCH 900222, MK 3222)
Catalog No. T76784 Copy Product Info
🥰Excellent
Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody targeting the p19 subunit of IL-23 with a Kd value of 136 pM, useful for studying psoriasis.
Tildrakizumab
Copy Product Info🥰Excellent
Catalog No. T76784
Synonyms SCH 900222, MK 3222
Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody targeting the p19 subunit of IL-23 with a Kd value of 136 pM, useful for studying psoriasis.
Tildrakizumab
Cas No. 1326244-10-3
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | - | In Stock | |
| 5 mg | $745 | In Stock | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,780 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:>95% (SDS-PAGE); 99.37% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody targeting the p19 subunit of IL-23 with a Kd value of 136 pM, useful for studying psoriasis. |
| Targets&IC50 | HeLa cells:23 pM |
| In vitro | Tildrakizumab inhibits IL-23-induced STAT3 signaling in HeLa cells expressing human IL-23Rα and IL-12Rβ1 receptors, with an IC50 of 23 pM[2], and reduces the affinity of IL-23 for IL-23Rα through negative allosteric modulation[2]. |
| In vivo | Tildrakizumab (100 mg/kg, subcutaneous injection, every two weeks, up to 9 months) demonstrates good tolerability in cynomolgus monkeys (toxicity study)[3]. |
| Synonyms | SCH 900222, MK 3222 |
| Reactivity | Human |
| Verified Activity | Immobilized Human IL-23 alpha Protein (His) (TMPY-00406) at 1 μg/mL (100 μL/well) can bind Tildrakizumab. The EC50 is 13.13 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-23a |
| Molecular Weight | 144.44 kDa |
| Cas No. | 1326244-10-3 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Tildrakizumab | purchase Tildrakizumab | Tildrakizumab cost | order Tildrakizumab | Tildrakizumab in vivo | Tildrakizumab in vitro | Tildrakizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.